Editas Medicine, Inc.
NASDAQ:EDITBiotechnology
+$0.07 today
- Market cap
- $273.18M
- Beta
- 2.10
- P/E (TTM)
- -2.4
- EPS (TTM)
- -$1.11
Volume 1.99M
Average 2.06M
EDIT Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Editas Medicine, Inc.NASDAQ: EDIT
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables dips below year-ago levels
Q1 FY2026 accounts receivables of $12.58M fell 20.1% year over year, behind the +685.7% change in trailing-twelve-month accounts receivables.
Context
- Accounts receivables amounted to 2.7% of revenue in FY2025, down 16.1 pp from a year earlier.
- Accounts receivables increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -20.1% toward the trailing-twelve-month pace of +685.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- 1.09M USD
- Year-over-year change
- +117.9%
- 4-year CAGR
- -34.1%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.09M | +117.9% |
| FY2024 | 2024-12-31 | (6.08M) | -20.6% |
| FY2023 | 2023-12-31 | (5.04M) | -3.4% |
| FY2022 | 2022-12-31 | (4.88M) | -184.4% |
| FY2021 | 2021-12-31 | 5.78M | — |
Accounts Receivables vs competitors
How EDIT compares with its peers on the latest reported figures
- EDIT's LTM Mar 2026 accounts receivables of $2.08M is the 2nd largest of the 9 companies compared; the peer median is $4.04K.
- Its year-over-year change of +685.7% is the highest of 6, against a peer median of -94.7%.
- Accounts receivables amounts to 5.4% of revenue for EDIT, versus a peer median of 1.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $5.47M | -147.5% | — | 12.1% | |
| LTM Mar 2026 | $2.08M | +685.7% | — | 5.4% | |
| LTM Mar 2026 | $1.37M | -94.7% | -18.2% | 2.1% | |
| LTM Mar 2026 | $378K | -56.7% | -57.2% | 3.4% | |
| LTM Mar 2026 | $17K | +200.0% | — | 0.4% | |
| LTM Mar 2026 | $8.07K | -96.4% | +481.9% | — | |
| LTM Sep 2026 | $0 | — | +334.4% | 0.0% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | — | |
SCTXScribe Therapeutics Inc. | — | — | — | — | — |
| Peer median (excluding EDIT) | $4.04K | -94.7% | +158.1% | 1.2% | |
Competitors are the stored peer set for EDIT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (192.5M) | (220.43M) | (153.22M) | (237.09M) | (160.06M) |
| Depreciation & Amortization | 5.05M | 6.34M | 6.06M | 5.81M | 5.28M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 43.4M | 29.29M | 19.8M | 21.42M | 10M |
| Change in Working Capital | (21.41M) | 8.18M | (1.59M) | 3.45M | (31.23M) |
| Accounts Receivables | 5.78M | (4.88M) | (5.04M) | (6.08M) | 1.09M |
| Inventory | (3.35M) | 0 | 0 | 0 | 0 |
| Accounts Payables | (1.14M) | 4.37M | (1.49M) | (2.29M) | (2.89M) |
| Other Working Capital | (22.71M) | 8.69M | 4.94M | 11.82M | (29.43M) |
| Other Non-Cash Items | 1.66M | (724K) | (3.23M) | (3.87M) | 10.77M |
| Operating Cash Flow | (163.8M) | (177.35M) | (132.18M) | (210.28M) | (165.24M) |
| Capital Expenditures | (7.98M) | (4.12M) | (4.72M) | (8.83M) | (607K) |
| Acquisitions (Net) | 46.49M | 18K | 0 | 0 | 269K |
| Purchases of Investments | (408.89M) | (315.19M) | (258.52M) | (86.22M) | 0 |
| Sales of Investments | 362.4M | 433.35M | 259.51M | 257.19M | 139.01M |
| Other Investing Activities | (46.49M) | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (54.47M) | 114.07M | (3.73M) | 162.15M | 138.67M |
| Debt Repayment | 0 | 0 | 0 | 0 | (2.87M) |
| Common Stock Issued | 249.46M | 1.28M | 117.08M | 56.03M | 43.34M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 32.65M | 0 | 960K | 0 | 0 |
| Financing Cash Flow | 282.11M | 1.28M | 118.04M | 56.03M | 40.47M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 63.84M | (62M) | (17.87M) | 7.89M | 13.9M |
| Free Cash Flow | (171.78M) | (181.47M) | (136.9M) | (219.11M) | (165.85M) |
Editas Medicine, Inc.
NASDAQ:EDIT
Intrinsic Alpha fair value
Locked
Current Price
$1.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.